MNST

Monster is a genuinely high-quality business, and FY2025 shows it firing on all cylinders. Revenue grew 10.7% to $8.29B — the latest step in a steady five-year climb ($5.54B → $6.31B → $7.14B → $7.49B → $8.29B) — while net income jumped 26.3% to $1.91B as gross profit (+14.4%) and operating income (+25.3%) outpaced the top line, signaling margin recovery from prior-year input-cost pressure. Margins are elite for a consumer-staples name: 55.8% gross, 29.2% operating, 23.0% net, with 23.1% ROE. The balance sheet is a fortress — $2.09B cash against just $374M long-term debt and a 3.7x current ratio ($5.36B / $1.45B) — and the model is asset-light, with capex cut in half to $132M and $2.10B of operating cash flow. This is a net-cash compounder with real reinvestment optionality.

The catch is price, not quality. At $91.34 the stock trades at 40.1x FY diluted EPS and 10.8x sales — a rich multiple even for a double-digit grower. Earnings growth (+26%) flatters a PEG-style read, but that pace was partly a margin-recovery rebound off FY2024's dip ($1.51B net income), not a durable run-rate; revenue growth of ~11% is the steadier signal, and against it 10.8x sales leaves little margin for error. The 97% collapse in buybacks to $104M (from a large prior-year program) means less per-share support, and the $2.28 EPS figure in the data carries a labeling anomaly worth flagging. Net income has also been lumpy year-to-year (1.38 → 1.19 → 1.63 → 1.51 → 1.91), so the smooth-compounder narrative is cleaner on revenue than on earnings.